Checkpoint inhibitors have changed a lot about how we treat cancer. They’ve also added a new layer of clinical complexity that most of us are still navigating: immune-related adverse events that can show up in almost any organ system, often at unpredictable times.
Grading an irAE, working through a differential on new neurologic symptoms in a patient on pembrolizumab, figuring out what to do next, these are the kinds of questions where having a fast, reliable AI reference really matters.
Oncologists are using Doximity Ask for exactly these moments, whether they’re on call, in clinic, or mid-infusion. Example prompts
- “Can you explain pembrolizumab immune-mediated neuropathy? How would it present?”
- “Ddx lower extremity peripheral neuropathy in a patient with stage 4 lung cancer, now on pembrolizumab, previously on carboplatin/paclitaxel”
- “CRS meaning (cytokine release syndrome secondary to immunotherapy for breast cancer)”
- “Durvalumab side effects”
These tend to be the on-call questions, the mid-infusion flags, the follow-up visit surprises that come with managing patients on checkpoint inhibitors.
Available when you need it
Immune-mediated toxicity doesn’t keep business hours, and neither does Doximity Ask. Because it’s designed for physicians and is HIPAA-compliant, you can include patient-specific context in your questions, the stage, the prior treatment history, the specific symptoms, and get back responses calibrated to clinical decision-making rather than general wellness guidance. That’s something a generic AI tool can’t reliably offer.
Try your next immunotherapy question at Doximity Ask. 
